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OBJECTIVE
Clinical isolates of Aspergillus from Portuguese hospitals were screened to
determine which, if any, of the cryptic species of Aspergillus were involved in
patient infections.
RESULTS & DISCUSSION
 A total of 57 Aspergillus isolates were collected.
 Among the collected isolates, six species-complexes were detected by ITS
sequencing, and were distributed as follows: Fumigati (29 isolates; 50.9%), Flavi
(12 isolates; 21.0%), Nigri (9 isolates; 15.8%), Terrei (3 isolates; 5.3%), Nidulantes
(2 isolates; 3.6%) and Versicolores (2 isolates; 3.6%) (Table 1).
 Three misidentifications at the species-complex level (based on morphology) were
resolved by ITS sequencing (isolates 12-59, 12-60 and INSA9) (Table 1).
METHODS
Over a one year, isolates of Aspergillus were collected from 10 health
institutions in Portugal.
All isolates were plated for growth as single colonies on malt extract
agar (2%) with chloramphenicol (0.05 g/L) These isolates were identified on the
basis of macro and microscopic morphology and through the use of molecular tools.
Genomic DNA was prepared from each isolate and the sequencing of
the Internal Transcribed Spacers (ITS) regions was performed to achieve the
species-complex, whereas β-tubulin and calmodulin sequencing was done to
achieve the correct species identification.
INTRODUCTION
Correct identification of Aspergillus species is important given that sibling/ cryptic
species may show different susceptibilities to antifungal and also because sharper
definition of species may facilitate epidemiological studies.
 Isolates identified as belonging to the Fumigati complex were found to be
more frequently recovered in clinical samples than were the other
complexes (P<0.001), being more frequently recovered from respiratory
specimens (P<0.001).
 Isolates no. 12-47 and INSA7 were identified morphologically only to the
genus level (Aspergillus sp.), but both were classified as belonging to the
Versicolores complex by molecular methodologies.
 Eleven isolates (19.3%) belonging to seven Aspergillus cryptic species
were identified (Table 1, in red). Seven of those isolates belonged to the Nigri
complex (cryptic species A. brasiliensis, A. awamorii and A. tubigensis), two
belonged to the Versicolores complex (cryptic species A. sidowii and A.
fructus), one to the Fumigati complex (cryptic species A. lentulus), and one to
the Nidulantes complex (cryptic species Emmericella echinulata)








12 - 26 Hospital # 1 Sputum A. fumigatus Fumigati A. fumigatus
12 - 27 Hospital # 1 Sputum A. fumigatus Fumigati A. fumigatus
12 - 28 Hospital # 1 Bronchial secretions A. fumigatus Fumigati A. fumigatus
12 - 29 Hospital # 1 Bronchial secretions A. fumigatus Fumigati A. fumigatus
12 - 30 Hospital # 1 Sputum A. fumigatus Fumigati A. fumigatus
12 - 31 Hospital # 1 Bronchoalveolar lavage A. fumigatus Fumigati A. fumigatus
12 - 32 Hospital # 1 Bronchoalveolar lavage A. flavus Flavi Not identified to species level
12 - 33 Hospital # 1 Bronchoalveolar lavage A. flavus Flavi A. flavus
12 - 34 Hospital # 2 Sputum A. flavus Flavi Not identified to species level
12 - 35 Hospital # 2 Sputum A. niger Nigri A. niger
12 - 36 Outpatient NIH Unknown A. flavus Flavi A. flavus
12 - 37 Hospital # 3 Bronchial secretions A. flavus Flavi A. flavus
12 - 38 Outpatient NIH Stool A. niger Nigri A. tubigensis
12 - 39 Hospital # 1 Bronchoalveolar lavage A. fumigatus Fumigati A. fumigatus 
12 - 40 Hospital # 1 Auricular exudate A. fumigatus Fumigati A. fumigatus
12 - 41 Hospital # 1 Sputum A. niger Nigri A. awamorii 
12 - 42 Hospital # 4 Auricular pus A. fumigatus Fumigati A. fumigatus
12 - 43 Hospital # 3 Bronchial secretions A. fumigatus Fumigati A. fumigatus
12 - 44 Outpatient NIH Sputum A. fumigatus Fumigati A. fumigatus
12 - 45 Hospital # 5 Sputum A. fumigatus Fumigati A. fumigatus
12 - 46 Hospital # 6 Palate biopsy A. fumigatus Fumigati A. fumigatus
12 - 47 Outpatient NIH Bronchoalveolar lavage Aspergillus sp. Versicolores A. sidowii
12 - 48 Hospital # 7 Sputum A. fumigatus Fumigati A. fumigatus
12 - 49 Hospital # 7 Bronchial secretions A. fumigatus Fumigati A. fumigatus
12 - 50 Hospital # 7 Sputum A. fumigatus Fumigati A. fumigatus
12 - 51 Hospital # 7 Bronchoalveolar lavage A. fumigatus Fumigati A. fumigatus
12 - 52 Hospital # 7 Sputum A. fumigatus Fumigati A. fumigatus
12 - 53 Hospital # 7 Ascitic fluid A. fumigatus Fumigati A. fumigatus
12 - 54 Hospital # 7 Auricular exudate A. flavus Flavi A. flavus
12 - 55 Hospital # 7 Skull biopsy A. flavus Flavi A. flavus
12 - 56 Hospital # 7 Bronchial secretions A. flavus Flavi A. flavus
12 - 57 Hospital # 7 Unknown A. flavus Flavi A. flavus
12 - 59 Hospital # 7 Bronchoalveolar lavage A. candidus Terrei A. terreus
12 - 60 Hospital # 7 Auricular exudate A. candidus Flavi A. flavus
12 - 62 Hospital # 7 Bronchial secretions A. niger Nigri A. tubigensis
12 - 63 Hospital # 7 Nasal sinus aspirate A. flavus Flavi A. flavus
12 - 64 Portuguese NIH Bronchoalveolar lavage A. fumigatus Fumigati A. fumigatus
12 - 65 Portuguese NIH Auricular exudate A. niger Nigri A. awamorii 
12 - 66 Portuguese NIH Auricular exudate A. niger Nigri A. niger
12 - 67 Portuguese NIH Auricular exudate A. niger Nigri A. brasiliensis
12 - 68 Portuguese NIH Bronchial secretions A. fumigatus Fumigati A. fumigatus 
12 - 69 Portuguese NIH Sputum A. fumigatus Fumigati Not identified to species level
12 - 70 Portuguese NIH Sputum A. terreus Terrei A. terreus 
INSA1 Outpatient NIH Bronchoalveolar lavage A. flavus Flavi A. flavus
INSA2 Outpatient NIH Bronchoalveolar lavage A. fumigatus Fumigati A. fumigatus
INSA3 Hospital # 3 Unknown A. fumigatus Fumigati A. fumigatus
INSA4 Outpatient NIH Bronchoalveolar lavage A. fumigatus Fumigati A. fumigatus
INSA5 Hospital # 3 Unknown A. nidulans Nidulantes Emmericella echinulata
INSA6 Hospital # 8 Unknown A. fumigatus Fumigati A. fumigatus
INSA7 Outpatient NIH Bronchoalveolar lavage Aspergillus sp. Versicolores A. fructus
INSA8 Hospital # 3 Unknown A. fumigatus Fumigati A. fumigatus
INSA9 Hospital # 3 Unknown A. nidulans Fumigati A. lentulus
INSA10 Outpatient NIH Sputum A. niger Nigri A. awamorii 
INSA11 Hospital # 3 Unknown A. nidulans Nidulantes Emericella nidulans
INSA12 Outpatient NIH Sputum A. fumigatus Nigri A. tubigensis
INSA13 Hospital # 9 Mamary gland Biopsy A. fumigatus Fumigati A. fumigatus 
INSA14 Outpatient NIH bronchial secretions A. terreus Terrei A. terreus
Cryptic species of Aspergillus have significant prevalence in the clinic.
The identification of Aspergillus cryptic species among the collected
clinical isolates emphasizes the importance of a correct identification to
species level, since sibling species may have different antifungal
susceptibilities.
CONCLUSION 
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Table I. Morphological and molecular identification of the collected clinical isolates 
Correct identification of Aspergillus species is important given that sibling species may show variable
susceptibilities to multiple antifungal drugs and also because sharper definition of species may
facilitate epidemiological studies. Thus, we screened Aspergillus clinical isolates from Portuguese
hospitals to determine which, if any, of the cryptic species of Aspergillus were involved in patient
infections.
Over a one year period, Aspergillus isolates from Portuguese health institutions were collected.
These isolates were identified on the basis of microscopic morphology and through the use of
molecular tools. Genomic DNA was prepared from each isolate and the sequencing of the Internal
Transcribed Spacers (ITS) regions, specifically the ITS1 and ITS2 non-coding regions flanking the
5.8S rDNA was used to determine the species complex, whereas β-tubulin and calmodulin
sequencing was done to achieve the correct species identification.
Over the study period, 57 Aspergillus isolates from clinical samples were collected from 10
Portuguese health institutions. According to the morphological observations, 29 isolates were
identified as Aspergillus fumigatus, 11 A. flavus, 8 A. niger, 3 A. nidulans, 2 A. terreus, 2 A. candidus
and 2 Aspergillus sp. Among those isolates, six species-complexes were detected by ITS
sequencing, and were distributed as follows: Fumigati (50.1%), Flavi (21.0%), Nigri (15.8%), Terrei
(5.3%), Nidulantes (3.6%) and Versicolores (3.6%). β-tubulin and calmodulin sequencing resulted in
ten (17.5%) cryptic species being identified among the 57 isolates. Seven of those isolates belonged
to the Nigri complex (A. brasiliensis, A. awamorii, A. tubigensis), two to the Versicolores complex (A.
sidowii and A. fructus), one to the Fumigati complex (A. lentulus) and one to the Nidulantes complex
(Emmericella echinulata).
With rigorous application of molecular tools, cryptic species of Aspergillus are not uncommon in the
clinic. The identification of cryptic species among the collected clinical isolates of Aspergillus alerts
the clinician to isolates with reduced susceptibilities to antifungal drugs and emphasizes a correct
identification to species level.
ABSTRACT
NIH – National Institute of Health
